ABL1 and rheumatoid arthritis: For example, imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) is cardiotoxic due to its strong inhibition of the Abelson kinase (ABL) [22,23], making its long-term use questionable for treatment of active RA.